Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Papillary Thyroid Cancer Market Volume Analysis, Segments, Value Share and Key Trends 2016-2026

 



(Medical-NewsWire.com, September 13, 2016 ) Papillary thyroid cancer (PTC) also called papillary carcinoma is one of the most common type of thyroid cancer and it is most curable among other cancers. Follicular cancer, medullary cancer, and anaplastic cancer are other types of thyroid cancers. The prevalence rate of papillary thyroid cancer is 0.5-10 per 100,000 population. Papillary thyroid carcinoma presents as asymptomatic thyroid nodules, increasing the size of nodule in patient is the primary symptom for this disease. Cough, dyspnea and dysphagia are the severe stage symptoms of papillary thyroid cancer and lump or swelling in the neck parts are the physical symptoms of the papillary thyroid cancer. Age, gender and exposure to radiation affect the risk of papillary thyroid cancer. Itis more common in women than in men, and often occurs before age 45. People who have been exposed to large amounts of radiation, or who have had radiation therapy for medical problems in the head and neck have a more chance of getting thyroid cancer.

To treat papillary thyroid cancer various methods are available which include surgical procedure, iodine therapy, thyroxin treatment and external radiotherapy. In surgical procedure, surgeon removes affected tissue from the neck. Iodine therapy is given to the patient post operatively to destroy normal thyroid remnants. External radiotherapy is indicated for the patients with age group 45 years and above.

Request for sample report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1659

The growth of thyroid tumor cells are controlled by thyrotropin and is inhibited by thyroxin, inhibition of thyrotropin with thyroxin increase the recurrence of survival rates. The most commonly used drugs in the treatment of papillary thyroid cancer are levothyroxine and radioiodine and antineoplastic agents such as cisplatin, doxorubicin and these drugs are used after the surgery and radiation therapy.

Papillary Thyroid Cancer Market has been classified on the basis of treatment and end user.

Papillary Thyroid Cancer by Treatment

Surgery

Iodine Therapy

Thyroxin Treatment

External Radiotherapy

Chemotherapy

Cisplatin

Doxorubicin

Drugs

Levothyroxine

Radioiodine

Papillary Thyroid Cancer by End User

Hospital

Oncology Centres

Hospital Pharmacies

Retail Pharmacies

In 2015, According to American Cancer Society (ACS), thyroid cancer accounts 47,230 in women and 15,220 in men in the U.S. and the incidence rate and mortality rate of thyroid cancer is high in women than in men. Thus, the increasing prevalence and incidence rate of thyroid cancers is expected to drive the overall papillary thyroid cancer. Increasing awareness about the cancer disease, raising government funds and reimbursement policies from Medicare and Medicaid are the key factors which are expected to propel the overall papillary thyroid cancer treatment market. The cost of the drugs and procedures is one of the major restraint for papillary thyroid cancer treatment market.

Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1659

Depending on geographic region, Papillary Thyroid Cancer Market is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is estimated to contribute maximum revenue share in the global market of Papillary Thyroid Cancer followed by Europe. Asia Pacific regions is expected to grow at a higher growth rate owing to high occurrence of cancer diseases. Middle East & Africa is expected to show a healthy growth rate in the forecast period

Key players of papillary thyroid cancer market are Mylan pharmaceuticals Inc., Baxter International Inc., Alara Pharmaceutical Corporation, Abbott laboratories, Bristol Myers co., Teva parenteral medicines Inc., Jerome Stevens Pharmaceuticals Inc., and App pharmaceuticals llc.



Future Market Insights

Abhishek Budholiya

2076928790

abhishek.b@futuremarketinsights.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC